Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 101–200 of 1,002
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000891 · Cited by 224
Self-citationExosome-Based Smart Drug Delivery Tool for Cancer Theranostics
Kar, R., Dhar, R., Mukherjee, S., Nag, S., Gorai, S., Mukerjee, N., Mukherjee, D., Vatsa, R., Chandrakanth Jadhav, M., Ghosh, A., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01329 · Cited by 210
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC: CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 205
Lactate dehydrogenase: a marker of diminished antitumor immunity
Van Wilpe, S., Koornstra, R., Den Brok, M., De Groot, J. W., Blank, C., De Vries, J., Gerritsen, W., & Mehra, N. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731942 · Cited by 208
“Additionally, two recent phase III trials showed that that the combination of anti-PD-(L)1 and VEGF inhibitors is superior to anti–VEGF monotherapy in RCC.(83,84) The combination of anti-angiogenic therapy and checkpoint inhibitors is currently also being studied in many other tumor types.”
BackgroundInfluentialResearch Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 199
Dai, S., Zeng, H., Liu, Z., Jin, K., Jiang, W., Wang, Z., Lin, Z., Xiong, Y., Wang, J., Chang, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001823 · Cited by 206
Self-citationBelzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313906 · Cited by 189
Self-citationImmune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 206
Hack, S. P., Spahn, J., Chen, M., Cheng, A.-L., Kaseb, A., Kudo, M., Lee, H. C., Yopp, A., Chow, P., & Qin, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0162 · Cited by 209
Self-citationSarcomatoid renal cell carcinoma: biology, natural history and management
Blum, K. A., Gupta, S., Tickoo, S. K., Chan, T. A., Russo, P., Motzer, R. J., Karam, J. A., & Hakimi, A. A. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00382-9 · Cited by 203
Understanding tumour endothelial cell heterogeneity and function from single-cell omics
Zeng, Q., Mousa, M., Nadukkandy, A. S., Franssens, L., Alnaqbi, H., Alshamsi, F. Y., Safar, H. A., & Carmeliet, P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00591-5 · Cited by 194
The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities
Elias, R., Zhang, Q., & Brugarolas, J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000480 · Cited by 205
Albiges, L., Powles, T., Staehler, M., Bensalah, K., Giles, R. H., Hora, M., Kuczyk, M. A., Lam, T. B., Ljungberg, B., Marconi, L., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.05.022 · Cited by 206
“The Keynote-426 trial (NCT02853331) has recently reported results for the combination of pembrolizumab ted results for the front-line treatment of clear-cell mRCCa IMDC FAV: 31% IMD: 56% Poor: 13% MSKCC Not determined (ITT) PEMBRO + AXI: 15.1 (12.6– 17.7) SUN: 11.1 (8.7–12.5) HR 0.69 (95% CI: 0.57, 0.84) p 0.0001 (ITT…”
InfluentialSelf-citationCurrent Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
“Such immune checkpoints could induce a durable clinical benefit, including a long-lasting regression of the tumor and an extended stabilization in patients with advanced NSCLC, melanoma and RCC [18,73,74].”
BackgroundSmall molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024: Featured Updates to the NCCN Guidelines
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Bagshaw, H., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0008 · Cited by 195
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
Powles, T., Albiges, L., Bex, A., Grünwald, V., Porta, C., Procopio, G., Schmidinger, M., Suárez, C., & de Velasco, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.014 · Cited by 193
Self-citationLee, C.-H., Shah, A. Y., Rasco, D., Rao, A., Taylor, M. H., Di Simone, C., Hsieh, J. J., Pinto, A., Shaffer, D. R., Girones Sarrio, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00241-2 · Cited by 187
Self-citationSun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
“Except for those eleven trials (Bang 2018; Borghaei 2015; Borghaei 2019; Brahmer 2015; Carbone 2017; Fradet 2019; Larkin 2018; Motzer 2015; Motzer 2019; Rini 2019; Socinski 2018), the remaining studies failed to provide information that helped us to assess allocation concealment.”
BackgroundInfluentialDatta, M., Coussens, L. M., Nishikawa, H., Hodi, F. S., & Jain, R. K. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237987 · Cited by 184
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Bourhis, M., Palle, J., Galy-Fauroux, I., & Terme, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616837 · Cited by 184
“As well as sunitinib, sorafenib can reduce Tregs and MDSC proportion in mouse models of liver cancer (58) and in HCC patients (59) or RCC (60).”
BackgroundInfluentialThe pro-tumorigenic host response to cancer therapies
Shaked, Y. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 181
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 181
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J., & Collins, D. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 182
Hypoxia-induced epithelial to mesenchymal transition in cancer
Hapke, R. Y., & Haake, S. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.012 · Cited by 178
“One of the leading frontline therapies for RCC is the combination of pembrolizumab and axitinib, an anti-PD-1 monoclonal antibody paired with a VEGF receptor tyrosine kinase inhibitor (VEGFR TKI)[160].”
BackgroundLiu, X.-D., Kong, W., Peterson, C. B., McGrail, D. J., Hoang, A., Zhang, X., Lam, T., Pilie, P. G., Zhu, H., Beckermann, K. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15959-6 · Cited by 177
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
De Martin, E., Michot, J.-M., Rosmorduc, O., Guettier, C., & Samuel, D. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100170 · Cited by 175
Markham, M. J., Wachter, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C. S. M., Rodriguez-Galindo, C., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 171
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Pal, S. K., Tran, B., Haanen, J. B. A. G., Hurwitz, M. E., Sacher, A., Tannir, N. M., Budde, L. E., Harrison, S. J., Klobuch, S., Patel, S. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0102 · Cited by 168
Choueiri, T. K., Eto, M., Motzer, R., De Giorgi, U., Buchler, T., Basappa, N. S., Méndez-Vidal, M. J., Tjulandin, S., Hoon Park, S., Melichar, B., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00049-9 · Cited by 172
Self-citationLee, J. B., Kim, H. R., & Ha, S.-J. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 174
“Currently, the anti-PD-1 inhibitor alone or combined chemotherapy are treated in front-line setting in metastatic GC, advanced RCC, metastatic TNBC, MSI-H or dMMR colorectal cancer, metastatic SCCHN, metastatic NSCLC (42-55).”
BackgroundSharma, R., Kadife, E., Myers, M., Kannourakis, G., Prithviraj, P., & Ahmed, N. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01961-3 · Cited by 162
“Recently, a phase III trial, was conducted with 861 patients randomly receiving axitinib plus pembrolizumab, a PD-1 inhibitor, and sunitinib monotherapy in previously untreated patients with mRCC [111, 146].”
BackgroundTang, C., Msaouel, P., Hara, K., Choi, H., Le, V., Shah, A. Y., Wang, J., Jonasch, E., Choi, S., Nguyen, Q.-N., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00528-3 · Cited by 170
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 179
Genomic profiling in renal cell carcinoma
Dizman, N., Philip, E. J., & Pal, S. K. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0301-x · Cited by 169
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Albiges, L., Burotto, M., Szczylik, C., Zurawski, B., Yanez Ruiz, E., Maruzzo, M., Suarez Zaizar, A., Fein, L. E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212851 · Cited by 164
Self-citationCardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Di Palo, K. E., Okwuosa, T. M., Przespolewski, E. R., Dent, S., & on behalf of the American Heart Association Clinical Pharmacology Committee and Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Peripheral Vascular Disease (2022) · Circulation · doi:10.1161/cir.0000000000001056 · Cited by 150
Santoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 168
Quatrini, L., Mariotti, F. R., Munari, E., Tumino, N., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12113285 · Cited by 158
Modeling clear cell renal cell carcinoma and therapeutic implications
Wolf, M. M., Kimryn Rathmell, W., & Beckermann, K. E. (2020) · Oncogene · doi:10.1038/s41388-020-1234-3 · Cited by 154
Adachi, Y., Kamiyama, H., Ichikawa, K., Fukushima, S., Ozawa, Y., Yamaguchi, S., Goda, S., Kimura, T., Kodama, K., Matsuki, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2426 · Cited by 186
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 165
Plimack, E. R., Powles, T. B., Stus, V. P., Gafanov, R. A., Nosov, D., Waddell, T., Alekseev, B. Y., Pouliot, F., Melichar, B., Soulières, D., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.06.006 · Cited by 180
Self-citationBedke, J., Albiges, L. K., Umberto Capitanio, A., Giles, R. H., Hora, M., Lam, T. B. L., Ljungberg, B., Marconi, L. S., Klatte, T., Volpe, A., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.04.042 · Cited by 158
Self-citationCousin, S., Cantarel, C., Guégan, J., Gomez‐Roca, C., Metges, J., Adenis, A., Pernot, S., Bellera, C. A., Kind, M., Auzanneau, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3416 · Cited by 160
“Such combinations have already been assessed with success in renal cell carcinomas as illustrated by the recent approval of pembrolizumab plus axitinib and avelumab plus axitinib in the first-line setting for patients with advanced disease (13, 18).”
BackgroundSiva, S., Bressel, M., Wood, S., Shaw, M. G., Loi, S., Sandhu, S. K., Tran, B., Azad, A., Lewin, J. H., Cuff, K. E., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.12.006 · Cited by 164
Roles of CCL2-CCR2 Axis in the Tumor Microenvironment
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168530 · Cited by 145
Rizzo, A., Santoni, M., Mollica, V., Logullo, F. O., Rosellini, M., Marchetti, A., Faloppi, L., Battelli, N., & Massari, F. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029405 · Cited by 163
Vano, Y. A., Elaidi, R., Bennamoun, M., Chevreau, C., Borchiellini, D., Pannier, D., Maillet, D., Gross‐Goupil, M., Tournigand, C., Laguerre, B., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00128-0 · Cited by 166
Self-citationSantoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 153
Chowdhury, N., & Drake, C. G. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.07.009 · Cited by 160
Li, J., Chen, Y., Li, Y., Liu, N., & Ma, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01317-7 · Cited by 162
McGregor, B. A., McKay, R. R., Braun, D. A., Werner, L. L., Gray, K. P., Flaifel, A., Signoretti, S., Hirsch, M. S., Steinharter, J. A., Bakouny, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01882 · Cited by 159
“Median age, years (range) 52 (36-75) 62 (22-82) 61 (22-82)”
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., De Geest, B., Breckpot, K., Dirix, L., Feldman, S. A., van Criekinge, W., Thielemans, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 142
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N., & Neilan, T. G. (2021) · JACC: CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 141
Clinical Review on the Management of Metastatic Renal Cell Carcinoma
Tran, J., & Ornstein, M. C. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00419 · Cited by 156
Pal, S. K., McGregor, B., Suárez, C., Tsao, C.-K., Kelly, W., Vaishampayan, U., Pagliaro, L., Maughan, B. L., Loriot, Y., Castellano, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00939 · Cited by 140
Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Champiat, S., Tselikas, L., Farhane, S., Raoult, T., Texier, M., Lanoy, É., Massard, C., Robert, C., Ammari, S., de Baère, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0473 · Cited by 151
The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy
Lai, Y., Tang, F., Huang, Y., He, C., Chen, C., Zhao, J., Wu, W., & He, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.29969 · Cited by 139
“With the emergence of ICIs, the combination of TKIs (e.g., axitinib) and ICIs (e.g., pembrolizumab) has also been increasingly investigated (Rini et al., 2019).”
BackgroundApolo, A. B., Nadal, R., Girardi, D. M., Niglio, S. A., Ley, L., Cordes, L. M., Steinberg, S. M., Ortiz, O. S., Cadena, J., Diaz, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01652 · Cited by 143
“Median age, years (range) 56 (20-82) Male 48 (89)”
The expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 150
Treatment Landscape of Renal Cell Carcinoma
Chen, Y., Wang, L., Panian, J. A., Dhanji, S., Derweesh, I., Rose, B. S., Bagrodia, A., & McKay, R. R. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01161-5 · Cited by 140
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 151
“…successes have been observed in the first-line setting for advanced-stage RCC, with pembrolizumab–axitinib versus sunitinib (KEYNOTE-426 trial) 109 , pembrolizumab–lenvatinib versus sunitinib (CLEAR trial) 110,111 and nivolumab–cabozantinib versus sunitinib (CheckMate 9ER trial) 112 ; both…”
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 129
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Quhal, F., Mori, K., Bruchbacher, A., Resch, I., Mostafaei, H., Pradère, B., Schuettfort, V. M., Laukhtina, E., Egawa, S., Fajković, H., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.03.001 · Cited by 147
Vessel co-option and resistance to anti-angiogenic therapy
Kuczynski, E. A., & Reynolds, A. R. (2019) · Angiogenesis · doi:10.1007/s10456-019-09698-6 · Cited by 148
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Rassy, E., Flippot, R., & Albiges, L. K. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920907504 · Cited by 143
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 153
Mettu, N. B., Ou, F.-S., Zemla, T. J., Halfdanarson, T. R., Lenz, H.-J., Breakstone, R. A., Boland, P. M., Crysler, O. V., Wu, C., Nixon, A. B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.49040 · Cited by 126
Targeting the tumor microenvironment in renal cell cancer biology and therapy
Heidegger, I., Pircher, A., & Pichler, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00490 · Cited by 133
Bedke, J., Albiges, L. K., Umberto Capitanio, A., Giles, R. H., Hora, M., Lam, T. B. L., Ljungberg, B., Marconi, L. S., Klatte, T., Volpe, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.12.005 · Cited by 133
Self-citationMcDermott, D. F., Lee, J., Bjarnason, G. A., Larkin, J., Gafanov, R. A., Kochenderfer, M. D., Jensen, N. V., Donskov, F. N., Malik, J., Poprach, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02363 · Cited by 146
“Although the single-arm nature of this study limits conclusions, the safety data of the current analysis suggest that pembrolizumab monotherapy may be better tolerated than the approved PD-1–based and PD-L1–based combination therapies.(2-4) Treatment with pembrolizumab monotherapy may therefore be a potential treatmen…”
BackgroundMethodResultSelf-citationBang, Y., Golan, T., Dahan, L., Fu, S., Moreno, V., Park, K., Geva, R., de Braud, F., Wainberg, Z. A., Reck, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.007 · Cited by 138
Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
Zahnreich, S., & Schmidberger, H. (2021) · Cancers · doi:10.3390/cancers13112607 · Cited by 157
“Wilms tumor alterations of WT1, CTNNB1, WTX, TP53, and MYNC [416] syndromes including WAGR, Drash, Beckwith- Wiedemann, Sotos, Perlman, Edward’s, Frasier, BLM, LFS, and Simpson-Golabi- Behmel combination of surgery and CT comprising vincristine, dactinomycin, and doxorubicin in children with localized tumors plus EBRT…”
BackgroundThe therapeutic implications of immunosuppressive tumor aerobic glycolysis
Reinfeld, B. I., Rathmell, W. K., Kim, T. K., & Rathmell, J. C. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00727-3 · Cited by 150
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 145
“So far, five ICI-based combinations have been approved by the FDA (Table 2): nivolumab and ipilimumab [56– 58], pembrolizumab and axitinib [59, 60], avelumab and axitinib [61, 62], nivolumab and cabozantinib [63], and”
MethodRavi, P. K., Mantia, C. M., Su, C. T., Sorenson, K., Elhag, D., Rathi, N., Bakouny, Z., Agarwal, N., Zakharia, Y., Costello, B. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2169 · Cited by 130
Zhou, C., Wang, Y., Zhao, J., Chen, G., Liu, Z., Gu, K., Huang, M., He, J., Chen, J., Ma, Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3136 · Cited by 138
“Two phase III studies in metastatic renal cell carcinoma showed that the combination of angiogenesis inhibitor axitinib with either pembrolizumab or avelumab improved progression-free survival (PFS) and objective response rate (ORR) compared with sunitinib alone (12, 13).”
BackgroundResultMechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 138
Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021) · Cancers · doi:10.3390/cancers13174444 · Cited by 134
Singla, N., Hutchinson, R. C., Ghandour, R. A., Freifeld, Y. N., Fang, D., Sagalowsky, A. I., Lotan, Y., Bagrodia, A., Margulis, V., Hammers, H. J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.02.029 · Cited by 127
Nielsen, D. L., Juhl, C. B., Chen, I. M., Kellermann, L., & Nielsen, O. H. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102440 · Cited by 136
“A high incidence of grade 1–4 (37%-54%) and grade 3–4 diarrhea (up to 9%) [41,42] was reported for these combinations.”
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 204
Aggen, D. H., Ager, C. R., Obradović, A., Chowdhury, N., Ghasemzadeh, A., Mao, W., Chaimowitz, M. G., Bujanda, Z. A. L., Spina, C. S., Hawley, J. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1610 · Cited by 132
“The current standard-of-care treatment for first-line metastatic RCC involves either combination PD-1/CTLA-4 blockade (4) or combining an anti-PD-1/PD-L1 therapy with a VEGF-targeted tyrosine kinase inhibitor (TKI), such as axitinib (5, 6).”
BackgroundShah, A. Y., Kotecha, R. R., Lemke, E., Chandramohan, A., Chaim, J. L., Msaouel, P., Xiao, L., Gao, J., Campbell, M. T., Zurita, A. J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.003 · Cited by 131
Bergerot, P., Lamb, P., Wang, E., & Pal, S. K. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1399 · Cited by 124
“Axitinib has shown efficacy in combination with pembrolizumab or avelumab in treatment-na€ ve patients with mRCC (20, 21).”
BackgroundMethodTumor metastasis: Mechanistic insights and therapeutic interventions
Liu, M., Yang, J., Xu, B.-S., & Zhang, X. (2021) · MedComm · doi:10.1002/mco2.100 · Cited by 136
Fakih, M., Raghav, K. P. S., Chang, D. Z., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Tam, R., D’Adamo, D. R., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101917 · Cited by 134
Yang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12534 · Cited by 133
Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma
Lasorsa, F. M., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S. D., Crocetto, F., Tătaru, O. S., Autorino, R., Battaglia, M., Ditonno, P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123888 · Cited by 137
Immune checkpoint inhibitor combinations: Current efforts and important aspects for success
Kon, E., & Benhar, I. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.004 · Cited by 129
Lenvatinib in Management of Solid Tumors
Hao, Z., & Wang, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0407 · Cited by 132
“bination was compared with sunitinib in RCC in a phase III trial in the first-line setting [57].”
MethodZhao, Y., Chen, G., Chen, J., Zhuang, L., Du, Y., Yu, Q., Zhuang, W., Zhao, Y., Zhou, M., Zhang, W., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102106 · Cited by 136
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies
Liu, X., Zhang, J., Yi, T., Li, H., Tang, X., Liu, D., Wu, D., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00779-x · Cited by 136
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 129
Powles, T. B. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.016 · Cited by 134
Self-citation
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.